<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835560</url>
  </required_header>
  <id_info>
    <org_study_id>Livzon-IY-81149R</org_study_id>
    <nct_id>NCT02835560</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection</brief_title>
  <official_title>Efficacy and Safety of Ilaprazole Based Bismuth-containing Quadruple Regimen for the First-line Treatment of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Livzon Pharmaceutical Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Livzon Pharmaceutical Group Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple&#xD;
      regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg, Clarithromycin&#xD;
      500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID on the first line eradication treatment of&#xD;
      H.pylori.&#xD;
&#xD;
      Participants are defined as persons who have endoscopically confirmed on gastric or duodenal&#xD;
      ulcer(including scar stage), gastritis and dyspepsia confirmed to be H.pylori positive&#xD;
      patients in the biopsy and UBT test. For 14 days, participants treated as Esoprazole based&#xD;
      bismuth-containing quadruple regimen therapy therapy including Esoprazole 20mg, Bismuth&#xD;
      Potassium Citrate 220mg, Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID.&#xD;
      After treatment, the healing rate was evaluated in the UBT test and Biopsy at 49±5days from&#xD;
      the first day dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compared efficacy and safety of Ilaprazole based bismuth-containing quadruple&#xD;
      regimen therapy including Ilaprazole 5mg, Bismuth Potassium Citrate 220mg，Clarithromycin&#xD;
      500mg and Amoxicillin Cap(Amoxicillin) 1000mg BID on the first line eradication treatment of&#xD;
      H.pylori.&#xD;
&#xD;
      Participants are defined as persons who have endoscopically confirmed on gastric or duodenal&#xD;
      ulcer(including scar stage), gastritis and dyspepsia confirmed to be H.pylori positive&#xD;
      patients in the biopsy and UBT test. For 14 days, Participants treated as Esoprazole based&#xD;
      bismuth-containing quadruple regimen therapy therapy including Esoprazole 20mg, Bismuth&#xD;
      Potassium Citrate 220mg，Clarithromycin 500mg and Amoxicillin Cap (Amoxicillin) 1000mg BID.&#xD;
      After treatment, The healing rate was evaluated in the UBT test and Biopsy at 49±5days from&#xD;
      the first day dosing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate of Helicobacter pylori as assessed by UBT test</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Helicobacter Pylori Eradication Antibiotic</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ilaprazole-based quadruple therapy for 14 days: Ilaprazole 5mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esoprazole&#xD;
Esoprazole-based quadruple therapy for 14 days: Esoprazole 20mg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy</intervention_name>
    <description>Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy</intervention_name>
    <description>Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid</description>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar)&#xD;
             or gastritis confirmed to be H.pylori positive patients in the biopsy and UBT test.&#xD;
&#xD;
          -  Subject who fully understands conditions of clinical trial.&#xD;
&#xD;
          -  Subject who agrees to participate and spontaneously sign the ICF.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to any component of ilaprazole, Amoxicillin and Levofloxacin.&#xD;
&#xD;
          -  Subjects who are taking contraindicated medications for experimental and concomitant&#xD;
             drug.&#xD;
&#xD;
          -  Patients with abnormal levels in the laboratory tests.&#xD;
&#xD;
          -  Total Bilirubin, Creatinine&gt; 1.5 times upper limit of normal.&#xD;
&#xD;
          -  AST, ALT, Alkaline phosphatase, BUN&gt; 2 times upper limit of normal.&#xD;
&#xD;
          -  Administrated of PPI, antibiotic medication within 4 weeks prior to commencement of&#xD;
             the study.&#xD;
&#xD;
          -  Pregnant and/or lactating women.&#xD;
&#xD;
          -  Reproductive aged women not using contraception.&#xD;
&#xD;
          -  Uncontrolled diabetics.&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Uncontrolled liver dysfunction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>July 9, 2016</study_first_submitted>
  <study_first_submitted_qc>July 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2016</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

